TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors. - Plummer R; Sodergren MH; Hodgson R; Ryan BM; Raulf N; Nicholls JP; Reebye V; Voutila J; Sinigaglia L; Meyer T; Pinato DJ; Sarker D; et al. (Cell reports. Medicine, 2025)